Clinical Trial Finder

Inclusion Criteria:

• - Provide written informed consent.

• - Age 18-75 years old.

• - Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2.

• - Patients with histologically or radiologically confirmed MPP and fail to other systemic therapy.

• - Estimated life expectancy longer than 6 months.

• - Confirmed non-pregnancy and lactation.

During the entire study period and within 6 months after the last administration, the subjects and their spouses are willing to use efficient contraceptive measures.

• - Laboratory requirements: - Absolute granulocyte count (AGC) greater than 1.5 x 109/L; - Platelet count greater than 80 x 109/L; - Hemoglobin greater than 90g/L; - Serum bilirubin less than 1.5 x upper limit of normal (ULN); --)Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than 2.5 x ULN; - Serum creatinine less than 1.5 x ULN or creatinine clearance (CCr)≥60ml/min; - Doppler ultrasound assessment: left ventricular ejection fraction (LVEF) ≥ lower limit of normal value (50%).

Exclusion Criteria:

• - Patients who had been previously treated with anti-PD1, anti-PD-L1, or anti-PD-L2 medications were excluded from this trial.

• - Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 14 days prior to the first dose of trial treatment.

• - Has a known history of active TB (Bacillus Tuberculosis).

• - Has a known history of Human Immunodeficiency Virus (HIV).

• - Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA [qualitative] is detected).

• - Has an active infection requiring systemic therapy.

• - Didn't meet eligibility for organ function.

• - Abnormal coagulation (INR >1.5 or prothrombin time (PT) > ULN 4 seconds or APTT >1.5 ULN), bleeding tendency or being treated with thrombolytic or anticoagulant therapy.

• - Uncontrolled congestive heart failure .

This was a prospective observational study. Patients with histologically or radiologically confirmed MPP and fail to other systemic therapy were enrolled. Penpulimab will be administered intravenously at a dose of 200 mg every 3 weeks. Treatment continued until the patient exhibited radiographic or clinical disease progression or unacceptable adverse events.Plasma normetanephrine and metanephrine (MNs), 24-hour urinary catecholamine excretion (24hCA) were measured at baseline and every 1-3cycle. Contrast-enhanced computed tomography(CT) of chest, abdomen and pelvis were used to assess measurable target lesions at baseline and every 3 cycles. For patients who only had bone metastases or no measurable target lesions, The efficacy was evaluated by 18F-fluorodeoxyglucose (18F-FDG-PET/CT). The primary endpoint was objective response rate (ORR) and the disease control rate (DCR) per Response Evaluation Criteria In Solid Tumors(RECIST) 1.1/PERCIST1.0. Secondary endpoints included biochemical (catecholamine levels) response rate (BRR), progression-free survival (PFS) and safety.

Arms

Experimental: penpulimab

Penpulimab will be administered intravenously at a dose of 200 mg every 3 weeks. Treatment continued until the patient exhibited radiographic or clinical disease progression or unacceptable adverse events.

Interventions

Drug: - Penpulimab

Penpulimab will be administered intravenously at a dose of 200 mg every 3 weeks. Treatment continued until the patient exhibited radiographic or clinical disease progression or unacceptable adverse events.